TQ Quiz | Roadmap to Medical Management of Glaucoma (Pittsburgh 2025) by Events@optometricedu.com | Feb 16, 2025 | 2025 Pittsburgh, TQ Courses | 0 comments "*" indicates required fields This field is hidden when viewing the form@{:35}This field is hidden when viewing the formDate (Hidden) MM slash DD slash YYYY This field is hidden when viewing the formEvent Date (Hidden) MM slash DD slash YYYY This field is hidden when viewing the formEvent 90 days past date (Hidden) MM slash DD slash YYYY This field is hidden when viewing the formEvent Date Difference (Hidden)1. Prior to 2018, the last year that a new glaucoma medication was introduced that had a new Mechanism of Action (MOA) was?* A - 1990 B - 1994 C - 1996 D - 2000 2. Where is the aqueous humor produced?* A - Pigmented cells of the ciliary processes B - Uveoscleral meshwork C - Schlemm’s Canal D - Crystalline Lens 3. What is the primary (highest percentage) pathway for aqueous humor to exit the eye?* A - Ciliary Processes B - Trabecular outflow pathway C - Vortex Veins D - Uveoscleral meshwork 4. The trabecular meshwork consists of how many distinct layers?* A - 1 B - 2 C - 3 D - 4 5. Netarsudil appears to also act on the uveoscleral outflow pathway and can lower IOP in the ___?* A - Ciliary processes B - Episcleral venous system C - Posterior Chamber D - Choroid 6. Which of the following medications is classified as an alpha agonist?* A - brimonidine B - timolol C - dorzolamide D - tafluprost 7. Latanoprostene bunod (LBN) contains what important new molecule?* A - Nitrous Oxide B - Nitric Oxide C - Potassium chloride D - Bunod 8. Nitric Oxide lowers IOP by?* A - Increasing uveoscleral outflow B - Decreasing aqueous humor production C - Relaxing cells in the trabecular meshwork D - Inhibiting the norepinephrine transporter 9. The peak IOP reduction of latanoprostene bunod (LBN) in the Apollo Study was?* A - 7.1 mmHg B - 7.5 mmHg C - 8.1 mmHg D - 9.1 mmHg 10. The Voyager study demonstrated what percent IOP reduction for LBN from mean baseline IOP?* A - 23.2% B - 29.8% C - 34.6% D - 44.1% 11. The most common Adverse Reaction to LBN in the Apollo and Lunar Studies was?* A - Instillation site pain B - Eye pain C - Conjunctival hyperemia D - Eye Irritation 12. The Jupiter Study demonstrated what mean percent reduction of IOP from a baseline of 19.6mmHg?* A - 22.5% B - 23.6% C - 26.5% D - 28.%% 13. Sleep laboratory studies have found that LBN has what effect during the nocturnal time period?* A - Lowers ocular perfusion pressure B - Lowers IOP more than timolol C - Lowers IOP less than timolol D - Has no effect on IOP 14. Approximately what percent of open angle glaucoma in the USA is the “normal tension” variety?* A - 15% B - 25% C - 30% D - 50% 15. A recent (2022) independent research publication found that glaucoma and ocular hypertensive subjects treated with LBN for four had what finding?* A - Improved vessel density to the macular region B - Improved vessel density to the peripheral retina C - Improved vessel density to the to trabecular meshwork D - Improved vessel density to the iris 16. Netarsudil’s primary location of action on IOP reduction is?* A - Ciliary processes and aqueous humor production B - Trabecular meshwork and ROCK inhibition C - Episcleral veins and lowering of pressure D - Uveoscleral outflow pathway 17. Netarsudil is an inhibitor of?* A - Rho Kinase B - Nitric oxide C - Carbonic Anhydrase D - Bunod 18. The mean decrease of IOP by netarsudil in the Rocket studies was?* A - 4.1 mmHg B - 4.4 mmHg C - 4.6 mmHg D - 4.8 mmHg 19. Ocular side effects of netarsudil include each of the following EXCEPT?* A - Corneal striae B - Corneal verticillate C - Conjunctival hyperemia D - Conjunctival hemorrhage 20. Which glaucoma medication is now available in a preservative free (PF) formulation?* A - brimonidine B - LBN C - netarsudil D - latanoprost Personal InformationName* First Last Email* Phone*OE Tracker #License #Address* Street Address Address Line 2 City State / Province / Region ZIP / Postal Code AfghanistanAlbaniaAlgeriaAmerican SamoaAndorraAngolaAnguillaAntarcticaAntigua and BarbudaArgentinaArmeniaArubaAustraliaAustriaAzerbaijanBahamasBahrainBangladeshBarbadosBelarusBelgiumBelizeBeninBermudaBhutanBoliviaBonaire, Sint Eustatius and SabaBosnia and HerzegovinaBotswanaBouvet IslandBrazilBritish Indian Ocean TerritoryBrunei DarussalamBulgariaBurkina FasoBurundiCabo VerdeCambodiaCameroonCanadaCayman IslandsCentral African RepublicChadChileChinaChristmas IslandCocos IslandsColombiaComorosCongoCongo, Democratic Republic of theCook IslandsCosta RicaCroatiaCubaCuraçaoCyprusCzechiaCôte d'IvoireDenmarkDjiboutiDominicaDominican RepublicEcuadorEgyptEl SalvadorEquatorial GuineaEritreaEstoniaEswatiniEthiopiaFalkland IslandsFaroe IslandsFijiFinlandFranceFrench GuianaFrench PolynesiaFrench Southern TerritoriesGabonGambiaGeorgiaGermanyGhanaGibraltarGreeceGreenlandGrenadaGuadeloupeGuamGuatemalaGuernseyGuineaGuinea-BissauGuyanaHaitiHeard Island and McDonald IslandsHoly SeeHondurasHong KongHungaryIcelandIndiaIndonesiaIranIraqIrelandIsle of ManIsraelItalyJamaicaJapanJerseyJordanKazakhstanKenyaKiribatiKorea, Democratic People's Republic ofKorea, Republic ofKuwaitKyrgyzstanLao People's Democratic RepublicLatviaLebanonLesothoLiberiaLibyaLiechtensteinLithuaniaLuxembourgMacaoMadagascarMalawiMalaysiaMaldivesMaliMaltaMarshall IslandsMartiniqueMauritaniaMauritiusMayotteMexicoMicronesiaMoldovaMonacoMongoliaMontenegroMontserratMoroccoMozambiqueMyanmarNamibiaNauruNepalNetherlandsNew CaledoniaNew ZealandNicaraguaNigerNigeriaNiueNorfolk IslandNorth MacedoniaNorthern Mariana IslandsNorwayOmanPakistanPalauPalestine, State ofPanamaPapua New GuineaParaguayPeruPhilippinesPitcairnPolandPortugalPuerto RicoQatarRomaniaRussian FederationRwandaRéunionSaint BarthélemySaint Helena, Ascension and Tristan da CunhaSaint Kitts and NevisSaint LuciaSaint MartinSaint Pierre and MiquelonSaint Vincent and the GrenadinesSamoaSan MarinoSao Tome and PrincipeSaudi ArabiaSenegalSerbiaSeychellesSierra LeoneSingaporeSint MaartenSlovakiaSloveniaSolomon IslandsSomaliaSouth AfricaSouth Georgia and the South Sandwich IslandsSouth SudanSpainSri LankaSudanSurinameSvalbard and Jan MayenSwedenSwitzerlandSyria Arab RepublicTaiwanTajikistanTanzania, the United Republic ofThailandTimor-LesteTogoTokelauTongaTrinidad and TobagoTunisiaTurkmenistanTurks and Caicos IslandsTuvaluTürkiyeUS Minor Outlying IslandsUgandaUkraineUnited Arab EmiratesUnited KingdomUnited StatesUruguayUzbekistanVanuatuVenezuelaViet NamVirgin Islands, BritishVirgin Islands, U.S.Wallis and FutunaWestern SaharaYemenZambiaZimbabweÅland Islands Country Payment InformationPromotional CodePittsburgh 2025 - Roadmap to Medical Management of Glaucoma |TQ*After 90 days, pricing will increase to $30. Price: (Past 90 Days) Pittsburgh 2025 - Roadmap to Medical Management of Glaucoma | TQThis course was presented over 90 days ago. Due to this late submission of TQ, your TQ credit price is $30. Price: Retake Discount Price: Promotional Discount Price: (Past 90 Days) Retake Discount Price: (Past 90 Days) Promotional Discount Price: Credit Card* This field is hidden when viewing the formCourse Information (HIDDEN)This field is hidden when viewing the formCourse Name (HIDDEN)This field is hidden when viewing the formRetake Code (HIDDEN)This field is hidden when viewing the formQuiz URL (HIDDEN)Do not include ending backslash (aka no .com/)This field is hidden when viewing the formCE Hours Submit a Comment Cancel replyYour email address will not be published. Required fields are marked *Comment * Name * Email * Website
